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Dear Editor, 
With interest I read the article from Saito and col-
leagues about “the effects of raloxifene on bone metabo-
lism in hemodialysis patients with type 2 diabetes” (1). 
The article addresses the possibility of treatment with 
raloxifene for osteoporosis in these patients. Raloxifene, 
a selective estrogen receptor modulator could be a good 
option, because it has no known renal side effects like 
bisphosphonates. Additionally, bisphosphonate use in 
chronic kidney disease is associated with adynamic bone 
disease, compared with a low bone turnover (2). In an-
other trial in a group of 17 postmenopausal hemodialysis 
patients raloxifene improved lumbar spine Bone Mineral 
Density (BMD) by 2.6% in 53% of the patients while 70% of 
the control group consisting of 10 aged-matched women 
showed a reduction in BMD by 4%. The effects of raloxi-
fene on serum calcium and serum iPTH level suggest it 
improves bone resorption (3). Primary, in these patients 
treatment of secondary hyperparathyroidism should be 
performed as is recommended (4). However of concern 
is the safety of raloxifene treatment in this patient group 
with multimorbidity. Long term studies should be per-
formed to determine the efficacy and safety of raloxifene 
in hemodialysis patients. 
Diabetes mellitus and chronic kidney disease both have 
a negative effect on bone metabolism and there is an 
increased risk of vascular complications. In the dialysis 
population the incidence of myocardial infarction and 
stroke is 5- to 15 fold higher (5) and cardiovascular mor-
tality is 10- to 30-fold higher (6) than seen in the general 
population (7-9).
In this hemodialysis population with or without dia-
betes mellitus I would expect an increased risk of fatal 
stroke with raloxifene therapy. Taking into account the 
data of the RUTH-trial in 10101 postmenopausal women 
with a mean age of 67 years, with a high Framingham 
Stroke Risk Score (FSRS) ( ≥ 13), a 75% increased risk of ral-
oxifene –associated fatal stroke was found. (HR 1.75; 95% 
CI, 1.01-3.02) (10). The FSRS includes the classical risk fac-
tors for cardiovascular disease including age, sex, systolic 
blood pressure, total and high density lipoprotein cho-
lesterol, diabetes mellitus, smoking and echocardiogram 
based left ventricular hypertrophy (11-13). This score was 
originally validated for people aged up to 75 years (14). 
The FSRS also seems to underestimate the vascular risk 
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in hemodialysis patients. The prevalence of traditional 
cardiovascular disease risk factors is very high in this he-
modialysisgroup, but seems not to explain all of the in-
creased cardiovascular risk (15). 
I would recommend a longer term randomized, double-
blind, placebo-controlled trial in hemodialysis patients 
(subgroup analysis with or without diabetes mellitus). 
Raloxifene versus placebo should be given for 3 years with 
attention to the change in BMD and monitoring fractures 
and vascular complications. First it should be shown that 
the number needed to treat to prevent fracture is clearly 
smaller than the number needed to harm in a clinical 
trial of the duration of the required raloxifene treat-
ment before raloxifene can be safely recommended as 
common practice in the treatment of osteoporosis in he-
modialysis patients. Saito et al. performed an important 
preliminary study that warrants the investment of such 
a trial to reach the quality standard of safe and evidence 
based therapy in this vulnerable patient group.
Financial Disclosure
None declared. 
References
1. Saito O, Saito T, Asakura S, Akimoto T, Inoue M, Ando Y, et al. Ef-
fects of Raloxifene on Bone Metabolism in Hemodialysis Pa-
tients With Type 2 Diabetes. Int J Endocrinol Metab. 2012;10 
(2):464-9. 
2. Amerling R, Harbord NB, Pullman J, Feinfeld DA. Bisphosphonate 
use in chronic kidney disease: association with adynamic bone 
disease in a bone histology series. Blood Purif. 2010;29 (3):293-9.
3. Tanaka M, Itoh K, Matsushita K, Moriishi M, Kawanishi H, Fukaga-
wa M. Effects of raloxifene on bone mineral metabolism in post-
menopausal Japanese women on hemodialysis. Ther Apher Dial. 
2011;15 Suppl 1:62-6.
4. Uhlig K, Berns JS, Kestenbaum B, Kumar R, Leonard MB, Martin 
KJ, et al. KDOQI US commentary on the 2009 KDIGO clinical prac-
tice guideline for the diagnosis, evaluation, and treatment of 
CKD–mineral and bone disorder (CKD-MBD). Am J Kid Dis. 2010;55 
(5):773-99.
5. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray D, Barre PE. 
Outcome and risk factors of ischemic heart disease in chronic 
uremia. Kidney Int. 1996;49 (5):1428-34.
6. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal 
disease: a new paradigm. Am J Kidney Dis. 2000;35 (4 Suppl 1):S117-
31.
7. Churchill DN, Taylor DW, Cook RJ, LaPlante P, Barre P, Cartier P, 
et al. Canadian Hemodialysis Morbidity Study. Am J Kidney Dis. 
1992;19 (3):214-34.
8. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated ath-
erosclerosis in prolonged maintenance hemodialysis. N Engl J 
Med. 1974;290 (13):697-701.
9. Rostand SG, Kirk KA, Rutsky EA. Relationship of coronary risk fac-
tors to hemodialysis-associated ischemic heart disease. Kidney 
Int. 1982;22 (3):304-8.
10. Barrett-Connor E, Cox DA, Song J, Mitlak B, Mosca L, Grady D. Ral-
oxifene and risk for stroke based on the framingham stroke risk 
score. Am J Med. 2009;122 (8):754-61.
11. Kagan A, Dawber TR, Kannel WB, Revotskie N. The Framingham 
study: a prospective study of coronary heart disease. Fed Proc. 
1962;21 (4)Pt 2:52-7.
12. Kannel WB. Coronary heart disease risk factors in the elderly. Am 
J Geriatr Cardiol. 2002;11 (2):101-7.
13. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J. Factors 
of risk in the development of coronary heart disease--six year 
follow-up experience. The Framingham Study. Ann Intern Med. 
1961;55:33-50.
14. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated cor-
onary risk profile. A statement for health professionals. Circula-
tion. 1991;83 (1):356-62.
15. Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, et 
al. Traditional cardiovascular disease risk factors in dialysis pa-
tients compared with the general population: the CHOICE Study. 
J Am Soc Nephrol. 2002;13 (7):1918-27.
